Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A van Elsas

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Investigative Dermatology|March 20, 1999
Influence of increased c-Myc expression on the growth characteristics of human melanomaH Schlagbauer-Wadl, M Griffioen, A van Elsas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 1997
Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccineA van Elsas, C Aarnoudse, C E van der Minne, et al.
Nature Medicine|February 14, 1998
bcl-2 antisense therapy chemosensitizes human melanoma in SCID miceB Jansen, H Schlagbauer-Wadl, B D Brown, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1995
CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cellsM J Visseren, A van Elsas, E I van der Voort, et al.
International Journal of Cancer|May 4, 1995
Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201A Van Elsas, H W Nijman, C E Van der Minne, et al.
The American Journal of Pathology|September 1, 1996
Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanomaA van Elsas, S F Zerp, S van der Flier, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2001
Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activationT J Sullivan, J J Letterio, A van Elsas, et al.
European Journal of Immunology|August 1, 1996
Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigenA van Elsas, S H van der Burg, C E van der Minne, et al.
The Journal of Experimental Medicine|September 19, 2001
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responsesR P Sutmuller, L M van Duivenvoorde, A van Elsas, et al.
The Journal of Experimental Medicine|August 22, 2001
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyA van Elsas, R P Sutmuller, A A Hurwitz, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Investigative Dermatology|March 20, 1999
Influence of increased c-Myc expression on the growth characteristics of human melanomaH Schlagbauer-Wadl, M Griffioen, A van Elsas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 1997
Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccineA van Elsas, C Aarnoudse, C E van der Minne, et al.
Nature Medicine|February 14, 1998
bcl-2 antisense therapy chemosensitizes human melanoma in SCID miceB Jansen, H Schlagbauer-Wadl, B D Brown, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1995
CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cellsM J Visseren, A van Elsas, E I van der Voort, et al.
International Journal of Cancer|May 4, 1995
Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201A Van Elsas, H W Nijman, C E Van der Minne, et al.
The American Journal of Pathology|September 1, 1996
Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanomaA van Elsas, S F Zerp, S van der Flier, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2001
Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activationT J Sullivan, J J Letterio, A van Elsas, et al.
European Journal of Immunology|August 1, 1996
Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigenA van Elsas, S H van der Burg, C E van der Minne, et al.
The Journal of Experimental Medicine|September 19, 2001
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responsesR P Sutmuller, L M van Duivenvoorde, A van Elsas, et al.
The Journal of Experimental Medicine|August 22, 2001
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyA van Elsas, R P Sutmuller, A A Hurwitz, et al.
Pageof 2